Contract packaging and manufacturing solutions provider Aphena Pharma has acquired a new bottling line to expand capacity.

The company has acquired an advanced high-speed, solid-dose bottling line that comes with an integrated cartoner.

Installed at its Cookeville facility in Tennessee, the line has a production capacity within a range of 15 to 20 million bottles a year. The production on the new line is expected to begin on 1 May.

The line will be used specifically to produce packaging solid-dose over-the-counter (OTC) products that fall under both branded and private-label categories.

Aphena sales executive vice-president Eric Allen said: “We have installed this new line for growth capacity so that we can continue to stay ahead of our current and future customers’ needs.

“It will allow Aphena to maintain a 50% capacity level for any new projects or surge capacity requirements.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Aphena Pharma Solutions is a contract packaging and manufacturing solutions provider for a range of markets, including pharmaceutical, consumer health and medical device.

The company has two separate Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA)-registered sites in the US. It manages solid dose, liquids, gels, creams, ointments, foams, suspensions and lotions.

In October 2019, the company announced an investment of $7m dedicated to the company-wide expansion project for future growth opportunities.

Targeted expansion areas includes additional manufacturing space Maryland, advanced custom blending suites and a 30,000ft² expansion of the Tennessee facility.

It also includes the addition of two advanced tri-mix blending tanks with counter-rotating sweep and high-shear mixing with vacuum for small and large batching.